Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Capital Expenditures (2022 - 2026)

Core Laboratories filings provide 5 years of Capital Expenditures readings, the most recent being $1.5 million for Q1 2026.

  • On a quarterly basis, Capital Expenditures fell 46.79% to $1.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.9 million, a 26.48% decrease, with the full-year FY2025 number at $11.2 million, down 5.71% from a year prior.
  • Capital Expenditures hit $1.5 million in Q1 2026 for Core Laboratories, down from $2.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.4 million in Q3 2025 to a low of -$7.0 million in Q4 2022.
  • Median Capital Expenditures over the past 5 years was $2.7 million (2022), compared with a mean of $1.8 million.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 4364.47% in 2024 and later crashed 141.67% in 2025.
  • Core Laboratories' Capital Expenditures stood at -$7.0 million in 2022, then soared by 98.92% to -$76000.0 in 2023, then skyrocketed by 4364.47% to $3.2 million in 2024, then dropped by 9.16% to $2.9 million in 2025, then crashed by 49.66% to $1.5 million in 2026.
  • The last three reported values for Capital Expenditures were $1.5 million (Q1 2026), $2.9 million (Q4 2025), and $7.4 million (Q3 2025) per Business Quant data.